We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Retinal Changes in Systemic Darbepoetin Alpha Treatment in Patients With Diabetes Mellitus (EPOinDR)

This study has been terminated.
(Patient recruitment was not sufficient to achieve the needed patient numbers.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00704652
First Posted: June 25, 2008
Last Update Posted: April 7, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Amgen
Information provided by (Responsible Party):
Gabor Deak, Medical University of Vienna
  Purpose
The purpose of this study is to determine whether systemic administration of darbepoetin alpha results in the progression or regression of diabetic macular edema.

Condition
Diabetic Retinopathy

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Evaluation of Functional and Morphological Retinal Changes in the Course of Systemic Aranesp Treatment in Patients With Diabetes Mellitus

Resource links provided by NLM:


Further study details as provided by Gabor Deak, Medical University of Vienna:

Primary Outcome Measures:
  • Morphologic changes in the retina detected by HD-OCT following darbepoetin alpha therapy compared to control patients [ Time Frame: 9 month ]

Secondary Outcome Measures:
  • Functional improvement in best corrected visual acuity (BCVA) and microperimetry following darbepoetin alpha therapy compared to control patients. [ Time Frame: 9 month ]
  • Changes in anterior chamber flare and cell count following darbepoetin alpha therapy compared to control patients. [ Time Frame: 9 month ]
  • Changes in the fundus image and fluorescein angiographic features following darbepoetin alpha therapy compared to control patients. [ Time Frame: 9 month ]
  • Changes in blood count, chemistry, Astrup and blood clotting following darbepoetin alpha therapy compared to control patients. [ Time Frame: 9 month ]

Enrollment: 5
Study Start Date: May 2008
Study Completion Date: September 2009
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
A
Diabetic patients suffering from renal insufficiency with stable haemoglobin levels (receiving no EPO supplementation)
B
Diabetic patients with renal insufficiency and in need of recombinant human EPO (darbepoetin alfa) substitution because of inadequate erythropoiesis. In both groups the target haemoglobin level is 10-12 gHb/ml, all treatment is performed according to label.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Diabetic patients with min. Grade 2 renal insufficiency, and in Group B with anemia that is to be treated with systemic ESA therapy.
Criteria

Inclusion Criteria:

Group A:

  • Males and females aged 18 to 80 yrs
  • Diabetes mellitus type 1 or 2
  • Haemoglobin level above the treatment threshold level (as described in the drug description)
  • Receiving no darbepoetin alfa treatment
  • Best Corrected Visual Acuity (BCVA) better than 20/200
  • No clinically significant macular edema (CSME) or CSME already treated with laser photocoagulation.

Group B:

  • Males and females aged 18 to 80 yrs
  • Diabetes mellitus type 1 or2
  • Anaemia (due to renal failure), haemoglobin level under the treatment threshold level before the initialisation of the therapy (as described in the drug label)
  • Starting to receive darbepoetin alfa treatment (darbepoetin alfa, Aranesp, Amgen)
  • BCVA better than 20/200
  • No clinically significant macular edema (CSME) or CSME already treated with laser photocoagulation.

Exclusion Criteria:

  • History of retinal disease other than DR
  • History of intraocular surgery, including laser treatment in the past 4 month
  • A major change in the insulin treatment of the patient in the past 4 month or during the follow up period.
  • Inability to communicate in German or English
  • Dementia; inability to follow commands
  • Epilepsy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00704652


Locations
Austria
Departmen of Ophthalmology, Medical Unversity of Vienna
Vienna, Austria, 1090
Sponsors and Collaborators
Medical University of Vienna
Amgen
Investigators
Principal Investigator: Ursula Schmidt-Erfurth, Prof. Departmen of Ophthalmology, Medical Unversity of Vienna
  More Information

Responsible Party: Gabor Deak, MD, Medical University of Vienna
ClinicalTrials.gov Identifier: NCT00704652     History of Changes
Other Study ID Numbers: 394/2007
First Submitted: June 23, 2008
First Posted: June 25, 2008
Last Update Posted: April 7, 2015
Last Verified: April 2015

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetic Retinopathy
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Retinal Diseases
Eye Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications
Darbepoetin alfa
Hematinics